European Training Network on targeted cancer therapy

Call for applications: November 4th – December 31st 2019

The Marie-Sklodowska-Curie European Training Network **Magicbullet::Reloaded** will develop and employ approaches for selective, targeted delivery of a panel of anticancer drugs for directed tumor therapy. The ETN will recruit **15 highly talented early stage researchers (ESR)** who will be involved in all stages of drug development, ranging from Synthetic Chemistry over Medicinal Chemistry to Tumor Biology and Assay Development in a highly cross-linked, inter-sectoral research network between academia and industry. This network warrants cutting-edge interdisciplinary education, supplemented by a well-balanced and tailor-made training in transferable soft skills, directly focussed on the demands and needs of each individual researcher.

This project has received funding from the **European Union's Horizon 2020 research and innovation programme** under the Marie Skłodowska-Curie grant agreement No 861316.

ESR Projects

ESR 01 - Bielefeld University, Germany: Implication of small molecule-drug conjugates containing HDAC inhibitors or tubulin-binding agents in immuno-oncology
Principal Investigator: Prof. Dr. Norbert Sewald *Planned Secondment:* Philochem AG, CH

ESR 02 - Eötvös Loránd University, Hungary: Development of peptide drug conjugates for the treatment of cancers causing high mortality
Principal Investigator: Prof. Dr. Gábor Mezõ *Planned Secondment:* Italfarmaco, IT

ESR 03 - ETH Zürich, Switzerland: Design and synthesis of novel Small Molecule-Drug Conjugates for the treatment of tumors
Principal Investigator: Prof. Dr. Dario Neri *Planned Secondment:* Bayer Pharma AG, DE

ESR 04 - Exiris SRL, Italy: Small molecule-drug conjugates containing HDAC inhibitors or tubulin-binding agents to enhance anti-tumor immune responses
Principal Investigator: Dr. Christian Steinkühler *Planned Secondment:* University of Helsinki, FI

ESR 05 - Fraunhofer ITEM, Germany: Identification of patient-specific targets to selectively treat tumor-associated macrophages (TAMs) in organotypic tumor slices of NSCLC and glioblastoma
Principal Investigator: Dr. Katherina Sewald *Planned Secondment:* Takis Biotech SRL, IT

ESR 06 - Heidelberg Pharma Research GmbH, Germany: Amatoxin conjugates with small molecule targeting molecules for the treatment of cancer
Principal Investigator: Prof. Dr. Andreas Pahl *Planned Secondment:* ETH Zürich, CH

ESR 07 - National Institute of Oncology, Hungary: Investigation of the effect of newly synthesized compounds on tumor cell proliferation in vitro and on tumor growth and metastasis in vivo
Principal Investigator: Dr. József Tóvári *Planned Secondment:* Heidelberg Pharma Research, DE

ESR 08 - Philochem AG, Switzerland: Design and synthesis of novel Small Molecule-Drug Conjugates for the treatment of tumors
Principal Investigator: Dr. Samuele Cazzamalli *Planned Secondment:* Bielefeld University, DE

ESR 09 - Takis Biotech SRL, Italy: Development of scFv-drug conjugates containing HDAC inhibitors or tubulin-binding agents to enhance anti-tumor immune responses
Principal Investigator: Dr. Giuseppe Roscilli *Planned Secondment:* University of Helsinki, FI

ESR 10 - Technische Universität Darmstadt, Germany: Design and synthesis of Multivalent Peptide Drug Conjugates for tumor targeting
Principal Investigator: Prof. Dr. Harald Kolmar *Planned Secondment:* Kineto Lab, HU

ESR 11 - Universitá degli Studi dell´ Insubria, Italy: Integrin ligand-immunomodulating agent conjugates for targeted immunoncological therapy
Principal Investigator: Prof. Dr. Umberto Piarulli *Planned Secondment:* Heidelberg Pharma Research, DE

ESR 12 - Universitá degli Studi di Milano, Italy: Design and synthesis of trifunctional peptidomimetic scaffolds for DNA-Encoded Chemical Libraries (DECLs) in the oncology area.
Principal Investigator: Prof. Dr. Cesare Gennari *Planned Secondment:* Philochem AG, CH

ESR 13 - University of Cologne, Germany: Targeting mitochondria with PDCs for inducing apoptosis in cancer cells
Principal Investigator: Prof. Dr. Ines Neundorf *Planned Secondment:* Exiris SRL, IT

ESR 14 - University of Helsinki, Finland: Targeted drug delivery to primary and secondary brain tumors
Principal Investigator: Prof. Dr. Pirjo Laakkonen *Planned Secondment:* Exiris SRL, IT

ESR 15 - University of Newcastle Upon Tyne, UK: Mass spectrometric analysis of peptide-drug conjugates in cells
Principal Investigator: Prof. Dr. Matthias Trost *Planned Secondment:* Bayer Pharma AG, DE

Further information can be found on www.magicbullet-reloaded.eu.